Praluent Approval History
- FDA approved: Yes (First approved July 24th, 2015)
- Brand name: Praluent
- Generic name: alirocumab
- Dosage form: Injection
- Company: Sanofi and Regeneron Pharmaceuticals, Inc.
- Treatment for: High Cholesterol, High Cholesterol, Familial Heterozygous
Praluent (alirocumab) is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor monoclonal antibody for the treatment of patients with heterozygous familial hypercholesterolemia or atherosclerotic heart disease who require additional lowering of LDL-cholesterol.
Development History and FDA Approval Process for Praluent
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.